FYI... Some of us have been associated the BioSilicon technology since Dec. 2000 and Qinetiq, the British MOD DERA that developed it. It has been a long time. Good to see it being put to good medical use. Have a read of some of the history.
GLTA
Under a December 2012 license agreement, amended and restated in March 2013, Enigma Therapeutics Limited (Enigma) acquired an exclusive, worldwide, royalty-bearing license for the development of BrachySil (now named OncoSil™), a BioSilicon product candidate for the treatment of pancreatic and other types of cancer. We received an upfront fee of $100,000 and are entitled to an 8% sales-based royalty, 20% of sublicense consideration and milestones based on aggregate product sales. Enigma is obligated to pay an annual license maintenance fee of $100,000, creditable during each ensuing twelve month period against reimbursable patent maintenance costs and sales-based royalties. The first annual license maintenance fee of $100,000 was paid in January 2014. Enigma has the right to terminate its license upon 60 days prior written notice.
OSL Price at posting:
16.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)